Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 14/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 14/20 | 0.43 |
| ▸ | PDE4A | P27815 | 7/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2986346 | 0.80 | SMN1; SMN2 (0.47) | KCNH2SMN1; SMN2PDE3BPDE3APDE4A | |
| SCHEMBL7263634 | 0.77 | KCNH2 (0.73) | KCNH2SMN1; SMN2PDE3BPDE3APDE4A | |
| SCHEMBL20702986 | 0.76 | PDE3B (0.65) | KCNH2SMN1; SMN2PDE3BPDE3APDE4A | |
| SCHEMBL20714543 | 0.76 | KCNH2 (0.56) | KCNH2SMN1; SMN2PDE3BPDE3APDE4A | |
| SCHEMBL9184755 | 0.75 | PDE3B (0.57) | KCNH2SMN1; SMN2PDE3BPDE3APDE4A | |
| SCHEMBL11118428 | 0.75 | SMN1; SMN2 (0.43) | KCNH2SMN1; SMN2PDE3BPDE3APDE4A | |
| SCHEMBL31018944 | 0.72 | AAK1 (0.55) | SMN1; SMN2PDE3BPDE3APDE4APDE4B | |
| SCHEMBL11371397 | 0.70 | SMN1; SMN2 (0.38) | KCNH2SMN1; SMN2PDE3BPDE3APDE4A | |
| SCHEMBL10353452 | 0.70 | SMN1; SMN2 (0.81) | KCNH2SMN1; SMN2PDE3BPDE3APDE4A | |
| SCHEMBL11738657 | 0.70 | PDE3B (0.55) | KCNH2SMN1; SMN2PDE3BPDE3APDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100273724-A1 | PEGYLATED ION CHANNEL MODULATING COMPOUNDS | CARDIOME PHARMA CORP. (CA) | 2010-10-28 | — | — | US | disclosed |
| US-20100273724-A1 | PEGYLATED ION CHANNEL MODULATING COMPOUNDS | CARDIOME PHARMA CORP. (CA) | 2010-10-28 | — | — | US | disclosed |
| US-7786119-B2 | Drug conjugates of ion channel modulating compounds | CARDIOME PHARMA CORP. (CA) | 2010-08-31 | — | — | US | disclosed |
| US-7786119-B2 | Drug conjugates of ion channel modulating compounds | CARDIOME PHARMA CORP. (CA) | 2010-08-31 | — | — | US | disclosed |
| US-7786119-B2 | Drug conjugates of ion channel modulating compounds | CARDIOME PHARMA CORP. (CA) | 2010-08-31 | — | — | US | disclosed |
| US-20080021005-A1 | Pegylated Ion Channel Modulating Compounds | CARDIOME PHARMA CORP. (CA) | 2008-01-24 | — | — | US | disclosed |
| US-20080021005-A1 | Pegylated Ion Channel Modulating Compounds | CARDIOME PHARMA CORP. (CA) | 2008-01-24 | — | — | US | disclosed |
| US-20080021005-A1 | Pegylated Ion Channel Modulating Compounds | CARDIOME PHARMA CORP. (CA) | 2008-01-24 | — | — | US | disclosed |
| EP-1729814-A2 | PEGYLATED ION CHANNEL MODULATING COMPOUNDS | Cardiome Pharma Corp. (CA) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005094897-A2 | PEGYLATED ION CHANNEL MODULATING COMPOUNDS | CARDIOME PHARMA CORP. (CA) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021005-A1 | Pegylated Ion Channel Modulating Compounds | KCNN3, KCNN2, KCNN1 | KCNH2 7/4885SMN1; SMN2 1263/4885PDE3B 2519/4885 |
| US-20100273724-A1 | PEGYLATED ION CHANNEL MODULATING COMPOUNDS | KCNN3, KCNN2, KCNN1 | KCNH2 7/4885SMN1; SMN2 1263/4885PDE3B 2519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.